To assess the effect of the four biomarkers on the overall immune profile of TCGA‐STAD patients, GC patients were categorized into the CHI3L1low + FCGBPhigh + VISIG2high + TFF2high and CHI3L1high + FCGBPlow + VISIG2low + TFF2low group based on the median expression levels of CHI3L1, FCGBP, VSIG2, and TFF2. This evidence concerns the gene VSIG2 and gastric cancer.